Antimicrob Agents Chemother 1992, 36:769–778.PubMedCrossRef 30. Ciric L, Mullany P, Roberts AP: Antibiotic and antiseptic resistance genes are linked on a novel mobile genetic
element: Tn6087. J Antimicrob Chemother 2011, 66:2235–2239.PubMedCrossRef 31. Knetsch CW, Hensgens selleck products MPM, Harmanus C, van der Bijl MW, Savelkoul PH, Kuijper EJ, et al.: Genetic markers for Clostridium difficile lineages linked to hypervirulence. Microbiology 2011, 157:3113–3123.PubMedCrossRef 32. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al.: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63–73.PubMedCrossRef 33. Griffiths D, Fawley W, Kachrimanidou M, Bowden R, Crook DW, Fung R, et al.: Multilocus sequence
typing of Clostridium difficile. J Clin Microbiol 2010, 48:770–778.PubMedCrossRef 34. Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, et al.: Macro and Micro Diversity of Clostridium difficile Isolates from Diverse Sources and Geographical Locations. PLoS One 2012, 7:e31559.PubMedCrossRef 35. Dingle KE, Griffiths D, Didelot X, Evans J, Vaughan A, Kachrimanidou M, et al.: Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One 2011, 6:e19993.PubMedCrossRef 36. Fawley WN, Freeman J, Smith C, Harmanus C, van den Berg RJ, Kuijper EJ, et al.: Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic Type 027 strains. J Clin Microbiol 2008, 46:954–960.PubMedCrossRef Tozasertib purchase 37. van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ: Typing and subtyping of Clostridium difficile isolates by using Palbociclib supplier multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007, 45:1024–1028.PubMedCrossRef 38. Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CH, Brazier JS, et al.: Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general
hospital in Buenos Aires, Argentina. Clin Microbiol Infect 2009, 15:1080–1086.PubMedCrossRef 39. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ: Characteristics and incidence of Clostridium difficile-associated disease, The Netherlands, 2005. Clin Microbiol Infect 2007, 13:1058–1064.PubMedCrossRef Aldehyde dehydrogenase 40. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC: Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999, 175:261–266.PubMedCrossRef 41. Hachler H, Kayser FH, Berger-Bachi B: Homology of a transferable tetracycline resistance determinant of Clostridium difficile with Streptococcus (Enterococcus) faecalis transposon Tn916. Antimicrob Agents Chemother 1987, 31:1033–1038.PubMedCrossRef 42. Brouwer MS, Allan E, Mullany P, Roberts AP: Draft Genome Sequence of the Nontoxigenic Clostridium difficile Strain CD37.